Bayer Collaboration Could Net $540M+ For Compugen

Bayer HealthCare will team up with Compugen on preclinical research toward antibody-based cancer immunotherapies against two potential immune checkpoint targets discovered by Compugen, with Bayer exercising full control over further development and holding worldwide commercialization rights for any resulting cancer therapeutics. The deal could generate more than $540 million for Compugen.

Under a collaboration and license agreement, Bayer agreed to pay Compugen $10 million up front, with up to $30 million in payments tied to preclinical milestones. Compugen is also eligible to receive over $500 million in potential payments tied to additional undisclosed milestones for both programs.

The company may also receive mid- to high-single-digit royalties on global net sales of any resulting products under the collaboration.

&quotImmunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen,&quot Prof. Andreas Busch, member of the Bayer HealthCare executive committee and head of global drug discovery, said in a statement.

Compugen said its researchers are developing specific therapeutic antibodies designed to fight cancer by blocking the function of immune checkpoint regulators, which may play a key role in immunosuppression, as well as reactivating the anti-tumor immune response of patients.

The Bayer collaboration is designed to expand Compugen's product pipeline, which according to the company's website includes 10 therapeutic protein and peptide product candidates and four monoclonal antibody (mAb) drug candidates against Compugen-discovered targets in oncology and immunology.

Compugen has identified targets for the mAbs through its Antibody Therapeutic Targets Discovery Platform and Protein Family Members Discovery Platform.


Genetic Engineering & Biotechnology News (GEN)Genetic Engineering & Biotechnology News (GEN)This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of stem-like CD4 T cells offers new hope for cancer immunotherapy